United Therapeutics CorporationUTHR

Why is United Therapeutics (UTHR) moving?

Q3 202612 Jul – 2 Oct 2026

▲4▼3

Legal Win and Organ Flights Boost UTHR, but Competition and Analyst Caution Linger

Court Blocks Liquidia's Yutrepia in PH-ILD A Delaware court blocked Liquidia's Yutrepia in PH-ILD, a key lung disease. This protects UTHR's Tyvaso franchise and sent shares up 12.5%.
This legal win directly removes a competitive threat and caused a sharp stock jump.
Manufactured Organs Flown on eVTOL United Therapeutics advanced its organ-delivery story by flying manufactured organs on the first U.S. eVTOL pilot flights, moving closer to its long-term goal of providing transplantable organs.
This milestone supports the company's long-term growth narrative and differentiates it from peers.
Phase 3 Data Supports Two FDA Filings New Phase 3 data supported two FDA filings, potentially expanding UTHR's product labels and driving future revenue growth.
Positive clinical data and regulatory filings are key catalysts for future sales.
Accelerated Buyback Returns $477.6 Million UTHR returned $477.6 million to shareholders via an accelerated buyback, signaling confidence and supporting the stock price.
Buybacks reduce share count and often boost investor sentiment.
Liquidia's Yutrepia Gains PAH Share Liquidia's Yutrepia continues to gain share in PAH, threatening UTHR's Tyvaso franchise. This competitive pressure weighs on the stock.
Ongoing competitive threat to core revenue stream.
Judge Criticizes Deceptive Patent Document A judge criticized UTHR for a deceptive, backdated patent-fight document, raising legal and reputational concerns.
This legal issue could lead to penalties and damage trust.
Goldman Sachs Initiates with Sell Rating Goldman Sachs initiated coverage with a Sell rating, doubting UTHR's 2029 targets. This analyst caution adds pressure on the stock.
Analyst downgrade can influence investor sentiment and stock performance.
New Tresmi Inhaler Could Defend Tyvaso The new Tresmi inhaler could help defend the Tyvaso franchise against competition, but its impact is uncertain and competition remains intense.
Potential positive product but not yet proven, so mixed effect.

September 20265 Aug – 2 Oct 2026

▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.
This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.
New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.
This is a fresh positive catalyst that strengthens the case for two potential new products.
Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.
This is a new capital-return action that directly affects share count and investor sentiment.
Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.
This is a new analyst action that introduces a notable counterweight to the positive patent news.

Latest5 Aug – 2 Oct 2026

▲3▼1

UTHR wins key patent ruling, but competition and analyst caution weigh

Court ruling blocks rival Yutrepia in PH-ILD A Delaware court ruled that Liquidia's Yutrepia infringes United Therapeutics' patent on inhaled treprostinil for PH-ILD. This could restrict Yutrepia's use in that lung condition, reducing competition for UTHR's Tyvaso and Tyvaso DPI, and UTHR may also win money damages. The stock jumped 12.5% on the news.
This is the biggest new event, directly lifting UTHR by weakening a rival and protecting its top-selling franchise.
New data supports two FDA filings United Therapeutics presented new analyses from its Phase 3 trials of ralinepag and inhaled treprostinil for IPF at European medical meetings. The data showed clinical benefits, supporting two FDA applications filed in June. If approved, these could expand UTHR's treatable patient groups and add billions in revenue.
This is a fresh positive catalyst that strengthens the case for two potential new products.
Company returns $477.6 million to shareholders United Therapeutics committed the last $477.6 million of its $2 billion buyback to an accelerated share repurchase. This brings total capital returned to about $4 billion in two and a half years. Buybacks reduce the number of shares, which can lift earnings per share and support the stock price.
This is a new capital-return action that directly affects share count and investor sentiment.
Goldman Sachs starts coverage with Sell rating Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, questioning whether the company can hit its 2029 revenue and earnings targets. The analyst doubts the ambitious pipeline can deliver as expected. This adds a fresh negative voice and could pressure the stock until upcoming FDA decisions provide clarity.
This is a new analyst action that introduces a notable counterweight to the positive patent news.

July 202612 Jul – 22 Jul 2026

▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.
New concrete validation of UTHR's organ business and logistics use case.
Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.
Shows the competitive threat to UTHR's main revenue source is growing.
Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.
New legal setback that could affect UTHR's ability to defend its PAH patents.
New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.
New product that may offset competitive and royalty pressures on UTHR's PAH business.

12 Jul – 22 Jul 2026

▲2▼2

UTHR's organ-delivery flights advance, but PAH competition and patent setback weigh

Manufactured organs flown on first eVTOL pilot flights United Therapeutics' manufactured organs were carried on the first US eVTOL integration pilot flights between Virginia and Maryland. This shows a real use for its organ products and could open a new delivery route, supporting the long-term growth story that helps lift the stock.
New concrete validation of UTHR's organ business and logistics use case.
Liquidia's Yutrepia keeps taking PAH market share Liquidia's competing PAH drug Yutrepia posted about $130 million in first-quarter sales, with thousands of patients starting it. It is winning new patients and expanding into more lung conditions, which threatens United Therapeutics' core Tyvaso franchise and caps the stock's upside.
Shows the competitive threat to UTHR's main revenue source is growing.
Judge criticizes United Therapeutics in patent fight A judge said United Therapeutics gave a deceptive and backdated answer in its patent dispute with Liquidia, and asked who changed the document. The stock slipped on the news. A bad ruling could weaken UTHR's legal position against a rival, so investors see added risk.
New legal setback that could affect UTHR's ability to defend its PAH patents.
New Tresmi inhaler could defend the Tyvaso franchise United Therapeutics unveiled Tresmi, a soft-mist inhaler its CEO called a category killer. It could replace lost Tyvaso DPI royalties and help hold off rivals like Yutrepia. A strong new product supports future sales, which is good for the stock.
New product that may offset competitive and royalty pressures on UTHR's PAH business.

Q2 202617 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

June 202617 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.

17 Jun – 9 Jul 2026

▲2▼2

Pipeline Wins and New Deals Offset Weak Sales and Rising Competition

FDA Approves LungFX Device United Therapeutics won FDA approval for its LungFX device, which helps assess donor lungs that would otherwise be discarded. This opens a new revenue stream in organ transplantation and supports the company's long-term growth story, pushing the stock up.
This is a new regulatory win that expands the company's business and is a fresh positive catalyst.
Acquires Thymmune for $140 Million United Therapeutics bought Thymmune Therapeutics for $140 million cash, adding a regenerative thymic cell therapy platform. This expands its pipeline in organ transplantation and immune therapies, signaling long-term growth and boosting investor confidence.
A new acquisition that adds technology and pipeline depth, directly affecting future growth prospects.
Q1 Revenue Miss and Decline United Therapeutics reported Q1 revenue of $781.5 million, down 1.6% from a year ago and missing estimates. This weak financial performance, especially compared to peers, weighs on the stock as investors worry about near-term sales trends.
A new earnings report showing a revenue miss and decline, which directly pressures the stock price.
Liquidia's YUTREPIA Gains Ground Liquidia's competing PAH drug YUTREPIA is growing fast, with annualized revenue near $520 million and most new patients treatment-naive. This competition threatens United Therapeutics' core PAH franchise, especially as its nebulized Tyvaso sales decline, capping upside.
A new update on a direct competitor's rapid growth, which increases competitive pressure on UTHR's key products.